As Miami-based Veru continues development of its enobosarm to prevent muscle wasting in patients being treated for obesity, ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

West Pharmaceutical Services rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.

U.K. regulators have launched a study into a possible genetic link between use of GLP-1s, such as Ozempic, Mounjaro and Wegovy, and acute pancreatitis. Yellow Card Biobank, a joint initiative of ...

Sensitivity analyses supported the robustness of the association between GLP-1 RA use and autoimmune disease risk. While GLP-1 RAs offer known glycemic and cardiometabolic benefits, these findings ...

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.